Finance

Beta
Lists
DCTH:NASDAQ
Delcath Systems Inc
$11.69
-2.01%
(-0.24) 1D
$11.69
0.00% (0.00)
After hours
Closed: Jun 18, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DCTH...
Open
$12.09
High
$12.18
Low
$11.64
Mkt. cap
403.56M
Avg. vol.
566.27K
Volume
582.71K
P/E ratio
1,951.59
52-wk high
$14.48
52-wk low
$8.12
EPS
$0.01
Beta
0.54
Shares outstanding
34.52M
No. of employees
156
Open
$12.09
High
$12.18
Low
$11.64
Mkt. cap
403.56M
Avg. vol.
566.27K
Volume
582.71K
P/E ratio
1,951.59
52-wk high
$14.48
52-wk low
$8.12
EPS
$0.01
Beta
0.54
Shares outstanding
34.52M
No. of employees
156
Analyst outlook
Analyst Ratings
Based on 3 analysts giving stock ratings to DCTH in the past 3 months
Strong Buy
Buy
3
Hold
0
Sell
0
12 month forecast
Based on 3 Wall Street analysts offering 12 month price targets for DCTH in the last 3 months.
Highest
Current $11.69
$30.00 (+156.63%)
Average
$25.50 (+118.14%)
Lowest
$21.00 (+79.64%)
News stories
From sources across the web
Profile
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
About Delcath Systems Inc
CEOGerard Michel
Employees156
Founded1988
HeadquartersQueensbury, New York, United States
SectorMedical device
Websitedelcath.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
24.16M
20.56M
20.73M
24.99M
Cost of goods sold
3.32M
2.62M
3.01M
3.74M
Cost of revenue
3.32M
2.62M
3.01M
3.74M
Research and development expenses
6.88M
7.99M
9.37M
9.82M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.37M
10.34M
10.53M
13.07M
Operating expense
18.25M
18.33M
19.90M
22.90M
Total operating expenses
21.57M
20.95M
22.91M
26.63M
Operating income
2.59M
-388.00K
-2.18M
-1.64M
Other non operating income
-34.00K
-33.00K
-7.00K
-58.00K
EBT including unusual items
3.20M
375.00K
-1.33M
-908.00K
EBT excluding unusual items
3.20M
375.00K
-1.33M
-908.00K
Income tax expense
508.00K
-455.00K
562.00K
162.00K
Effective tax rate
15.85%
-121.33%
-42.13%
-17.84%
Other operating expenses
-
-
-
-
Net income
2.70M
830.00K
-1.90M
-1.07M
Net profit margin
11.16%
4.04%
-9.15%
-4.28%
Earnings per share
0.07
0.02
-0.05
-0.03
Interest and investment income
649.00K
796.00K
857.00K
787.00K
Interest expense
-
-
-
-
Net interest expenses
649.00K
796.00K
857.00K
787.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
2.64M
-324.00K
-2.10M
-1.54M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer